Trius Therapeutics (TSRX) Underwriters Exercise Full Overallotment in Recent Offering
Tweet
Share
E-mailGet Alerts TSRX Hot Sheet
Join SI Premium – FREE
Trius Therapeutics, Inc. (Nasdaq: TSRX) today announced that the underwriters of its public offering that priced on January 26, 2012 have exercised in full their option to purchase an additional 1,290,000 shares of common stock. With the sale of the additional shares at a price to the public of $5.25 per share, the aggregate gross proceeds to Trius from this offering are expected to be approximately $51.9 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Trius. The offering, including the sale of the additional shares, is expected to close on or about January 31, 2012, subject to customary closing conditions.
Trius anticipates using the net proceeds from the offering for general corporate purposes, including clinical trial and other research and development expenses, capital expenditures, working capital and general and administrative expenses.
Trius anticipates using the net proceeds from the offering for general corporate purposes, including clinical trial and other research and development expenses, capital expenditures, working capital and general and administrative expenses.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Denarius Metals acquires 15% stake in Copper Giant, Trafigura invests
- Noodles & Company (NDLS) files $100M mixed shelf
- CoVolt Power files for proposed IPO
Create E-mail Alert Related Categories
Corporate News, Equity OfferingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
